)
Jan Westerblad
Associate Director, Norway
Since Jan started in the pharmaceutical industry in the early 1990s, he has held various commercial positions in small and large companies, both in Norway and in the Nordic Region. Since the beginning of 2000, Jan's focus has been in the field of orphan/ultraorphan disease and he's been involved/responsible for starting up Norwegian/Nordic commercial operations in several companies, latest Alnylam Pharmaceuticals